top of page
All Posts
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
October 16, 2025 Financing led by Bpifrance with co-leads Kurma Partners, Andera Partners and Angelini Ventures, followed by other prestigious new investors, Surveyor Capital (a Citadel company) and aMoon, and with renewed participation from all existing shareholders, including Pontifax, DawnBiopharma (a platform controlled by KKR), Pureos Bioventures and RA Capital Proceeds to advance lead program ADCX-020 into the clinic, with first IND and CTA filings planned by end 2025 F
ADCytherix
a few seconds ago3 min read
Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates
June 11, 2024 Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer. Founded by the team that founded and sold Emergence Therapeutics to Eli Lilly and Company. Seed round led by Pontifax and includes top-tier life science investors. Marseille, France, 11 June 2024 : Adcytherix SAS today announced its incorporation and seed funding of € 30 million to develop novel antibody-drug- conjugates (ADCs) for the treatment of high unmet need di
ADCytherix
Jun 11, 20241 min read
bottom of page